Provectus Biopha Financials
This page shows Provectus Biopha (PVCT) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
External financing, not commercial revenue, is keeping this development-stage operation functioning as assets and liquidity keep shrinking.
Across FY2023-FY2025, financing inflows repeatedly ran close to operating cash burn, leaving year-end cash below$307K each year instead of building an operating cushion. That pattern means losses are being bridged externally rather than softened by internal cash conversion, with FY2025 still requiring$3.1M of financing against-$3.3M of operating cash flow.
FY2025 revenue of
The balance sheet has become thinner, with assets shrinking from
Financial Health Signals
Based on FY2025 annual data, averaged across the last 3 years for performance metrics (most-recent year weighted highest). How this score is calculated →
Health score ≠ stock price. This rates the quality of Provectus Biopha's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Provectus Biopha's revenue declined 45.5% year-over-year, from $617K to $336K. This contraction results in a growth score of 0/100.
Provectus Biopha carries a low D/E ratio of -1.11, meaning only $-1.11 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 89/100, indicating a strong balance sheet with room for future borrowing.
Provectus Biopha's current ratio of 0.08 is below the typical benchmark, resulting in a score of 0/100. This tight liquidity could limit financial flexibility if cash inflows slow.
Provectus Biopha passes 1 of 9 financial strength tests. No profitability signals pass, 1 of 3 leverage/liquidity signals pass, neither operating efficiency signal passes.
Key Financial Metrics
Earnings & Revenue
Provectus Biopha generated $336K in revenue in fiscal year 2025. This represents a decrease of 45.5% from the prior year.
Provectus Biopha earned $-0.01 per diluted share (EPS) in fiscal year 2025. This represents an increase of 0.0% from the prior year.
Cash & Balance Sheet
Provectus Biopha held $251K in cash against $0 in long-term debt as of fiscal year 2025.
Provectus Biopha had 420M shares outstanding in fiscal year 2025. This represents an increase of 0.0% from the prior year.
Margins & Returns
Capital Allocation
Provectus Biopha invested $1.9M in research and development in fiscal year 2025. This represents a decrease of 7.5% from the prior year.
PVCT Income Statement
| Metric | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 | Q1'24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | N/A | N/A | $57K-79.4% | $279K+1844.1% | $14K-86.9% | $110K-57.0% | $255K+7.1% | $238K |
| Cost of Revenue | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| R&D Expenses | N/A | $346K-60.1% | $867K+123.1% | $389K-36.1% | $608K+46.9% | $414K-12.5% | $473K-14.9% | $556K |
| SG&A Expenses | N/A | $930K-6.2% | $991K+0.3% | $988K-43.3% | $1.7M+167.2% | $651K+12.9% | $577K+344.5% | $130K |
| Operating Income | N/A | -$1.3M+29.2% | -$1.8M-64.0% | -$1.1M+53.0% | -$2.3M-144.3% | -$956K-20.2% | -$795K-77.7% | -$447K |
| Interest Expense | N/A | -$48K+6.5% | -$51K+19.3% | -$64K-133.4% | $190K+424.4% | -$59K+4.3% | -$61K-8.0% | -$57K |
| Income Tax | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Income | N/A | -$1.3M+27.7% | -$1.8M-59.1% | -$1.1M+51.8% | -$2.4M-133.4% | -$1.0M-19.8% | -$847K-68.0% | -$504K |
| EPS (Diluted) | N/A | $0.00 | $0.00 | $0.00 | N/A | $0.00 | $0.00 | $0.00 |
PVCT Balance Sheet
| Metric | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 | Q1'24 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $698K+66.1% | $420K-41.9% | $722K+8.4% | $666K-33.8% | $1.0M+25.5% | $802K-6.4% | $856K-20.6% | $1.1M |
| Current Assets | $568K+104.3% | $278K-51.1% | $568K-12.5% | $649K-33.5% | $977K+28.5% | $760K-5.0% | $800K-20.7% | $1.0M |
| Cash & Equivalents | $251K+246.7% | $72K-81.2% | $386K-1.2% | $390K+27.0% | $307K+64.0% | $187K+533.7% | $30K+64.0% | $18K |
| Inventory | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Accounts Receivable | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Goodwill | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $7.0M+6.3% | $6.6M-0.2% | $6.6M+15.0% | $5.7M-17.8% | $7.0M+12.1% | $6.2M-25.6% | $8.4M-1.9% | $8.5M |
| Current Liabilities | $6.9M+6.6% | $6.5M-0.3% | $6.5M+13.2% | $5.7M-17.8% | $7.0M+12.1% | $6.2M-25.6% | $8.4M-1.7% | $8.5M |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Equity | -$6.3M-2.4% | -$6.2M-4.8% | -$5.9M-15.1% | -$5.1M+14.4% | -$6.0M-9.9% | -$5.4M+27.8% | -$7.5M-0.9% | -$7.4M |
| Retained Earnings | -$262.9M-0.4% | -$261.7M-0.5% | -$260.4M-0.7% | -$258.6M-0.4% | -$257.4M-0.9% | -$255.1M-0.4% | -$254.0M-0.3% | -$253.2M |
PVCT Cash Flow Statement
| Metric | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 | Q1'24 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$870K-3.5% | -$840K-60.5% | -$523K+52.2% | -$1.1M-19.9% | -$912K-61.4% | -$565K+25.9% | -$763K+27.0% | -$1.0M |
| Capital Expenditures | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Free Cash Flow | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Investing Cash Flow | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Financing Cash Flow | $1.0M+111.4% | $496K+5.6% | $470K-56.2% | $1.1M+36.1% | $788K+33.8% | $589K+0.1% | $589K-24.6% | $781K |
| Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
PVCT Financial Ratios
| Metric | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 | Q1'24 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Margin | N/A | N/A | -3132.8%-2738.7pp | -394.1%+15894.9pp | -16289.0%-15418.1pp | -870.9%-559.1pp | -311.7%-123.8pp | -187.9% |
| Net Margin | N/A | N/A | -3156.6%-2747.4pp | -409.2%+16108.5pp | -16517.7%-15593.4pp | -924.3%-592.2pp | -332.1%-120.4pp | -211.7% |
| Return on Equity | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Assets | N/A | -312.3%-61.1pp | -251.2%-80.0pp | -171.1%+64.1pp | -235.3%-108.8pp | -126.5%-27.6pp | -98.9%-52.2pp | -46.7% |
| Current Ratio | 0.08+0.0 | 0.04-0.0 | 0.09-0.0 | 0.11-0.0 | 0.14+0.0 | 0.12+0.0 | 0.10-0.0 | 0.12 |
| Debt-to-Equity | -1.11-0.0 | -1.07+0.1 | -1.120.0 | -1.12+0.0 | -1.17-0.0 | -1.15-0.0 | -1.11+0.0 | -1.14 |
| FCF Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Note: Shareholder equity is negative (-$6.3M), which causes debt-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.
Note: The current ratio is below 1.0 (0.08), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.
Similar Companies
Frequently Asked Questions
What is Provectus Biopha's annual revenue?
Provectus Biopha (PVCT) reported $336K in total revenue for fiscal year 2025. This represents a -45.5% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Provectus Biopha's revenue growing?
Provectus Biopha (PVCT) revenue declined by 45.5% year-over-year, from $617K to $336K in fiscal year 2025.
What is Provectus Biopha's operating cash flow?
Provectus Biopha (PVCT) generated -$3.3M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.
What are Provectus Biopha's total assets?
Provectus Biopha (PVCT) had $698K in total assets as of fiscal year 2025, including both current and long-term assets.
How much does Provectus Biopha spend on research and development?
Provectus Biopha (PVCT) invested $1.9M in research and development during fiscal year 2025.
What is Provectus Biopha's current ratio?
Provectus Biopha (PVCT) had a current ratio of 0.08 as of fiscal year 2025, which is below 1.0, which may suggest potential liquidity concerns.
What is Provectus Biopha's debt-to-equity ratio?
Provectus Biopha (PVCT) had a debt-to-equity ratio of -1.11 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Provectus Biopha's cash runway?
Based on fiscal year 2025 data, Provectus Biopha (PVCT) had $251K in cash against an annual operating cash burn of $3.3M. This gives an estimated cash runway of approximately 1 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
Why is Provectus Biopha's debt-to-equity ratio negative or unusual?
Provectus Biopha (PVCT) has negative shareholder equity of -$6.3M as of fiscal year 2025, which causes the debt-to-equity ratio to appear negative or not meaningful. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.
What is Provectus Biopha's Piotroski F-Score?
Provectus Biopha (PVCT) has a Piotroski F-Score of 1 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
How financially healthy is Provectus Biopha?
Provectus Biopha (PVCT) scores 15 out of 100 on our Financial Profile, indicating weak overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.